These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9731706)

  • 1. Characterization of the DNA-binding and dominant negative activity of v-erbA homodimers.
    Subauste JS; Koenig RJ
    Mol Endocrinol; 1998 Sep; 12(9):1380-92. PubMed ID: 9731706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimerization of v-erbA on inverted repeats.
    Zubkova I; Subauste JS
    Biochem Biophys Res Commun; 2002 May; 294(1):35-41. PubMed ID: 12054736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncoprotein P75gag-v-erbA represses thyroid hormone induced transcription only via response elements containing palindromic half-sites.
    Wahlström GM; Harbers M; Vennström B
    Oncogene; 1996 Aug; 13(4):843-52. PubMed ID: 8761306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequences required for the transition from monomeric to homodimeric forms of thyroid hormone receptor alpha and v-erbA.
    Zubkova I; Subauste JS
    Mol Cell Endocrinol; 2003 Jan; 199(1-2):61-72. PubMed ID: 12581880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimerization interfaces of v-erbA homodimers and heterodimers with retinoid X receptor alpha.
    Shen Q; Subauste JS
    J Biol Chem; 2000 Dec; 275(52):41018-27. PubMed ID: 11018031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of DNA binding sites for the V-erbA oncoprotein, the viral homolog to thyroid hormone receptor alpha.
    Harbers M; Wahlström GM; Vennström B
    J Steroid Biochem Mol Biol; 1998 Nov; 67(3):181-91. PubMed ID: 9879977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V-erba homodimers mediate the potent dominant negative activity of v-erba on everted repeats.
    Zubkova I; Subauste JS
    Mol Biol Rep; 2004 Jun; 31(2):131-7. PubMed ID: 15293789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V-erbA requires auxiliary proteins for dominant negative activity.
    Hermann T; Hoffmann B; Piedrafita FJ; Zhang XK; Pfahl M
    Oncogene; 1993 Jan; 8(1):55-65. PubMed ID: 8093812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the DNA binding specificity and function of v-ErbA and thyroid hormone receptor alpha 1.
    Subauste JS; Koenig RJ
    J Biol Chem; 1995 Apr; 270(14):7957-62. PubMed ID: 7713893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirements for repression of retinoid X receptor by the oncoprotein P75gag-v-erbA and the thyroid hormone receptors.
    Wahlström GM; Vennström B
    Mol Endocrinol; 1998 May; 12(5):645-53. PubMed ID: 9605927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoid X receptor alpha binds with the highest affinity to an imperfect direct repeat response element.
    Yang YZ; Subauste JS; Koenig RJ
    Endocrinology; 1995 Jul; 136(7):2896-903. PubMed ID: 7789315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A choice between transcriptional enhancement and repression by the v-erbA oncoprotein governed by one nucleotide in a thyroid hormone responsive half site.
    Andersson ML; Vennström B
    Oncogene; 2000 Jul; 19(32):3563-9. PubMed ID: 10951561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities.
    Hao E; Menke JB; Smith AM; Jones C; Geffner ME; Hershman JM; Wuerth JP; Samuels HH; Ways DK; Usala SJ
    Mol Endocrinol; 1994 Jul; 8(7):841-51. PubMed ID: 7984146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A domain containing leucine-zipper-like motifs mediate novel in vivo interactions between the thyroid hormone and retinoic acid receptors.
    Forman BM; Yang CR; Au M; Casanova J; Ghysdael J; Samuels HH
    Mol Endocrinol; 1989 Oct; 3(10):1610-26. PubMed ID: 2558297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA.
    Yen PM; Ikeda M; Brubaker JH; Forgione M; Sugawara A; Chin WW
    J Biol Chem; 1994 Jan; 269(2):903-9. PubMed ID: 7904604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-ErbA, but not v-ErbA, competes with a putative erythroid repressor for binding to the carbonic anhydrase II promoter.
    Rascle A; Ghysdael J; Samarut J
    Oncogene; 1994 Oct; 9(10):2853-67. PubMed ID: 7916146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer in vivo.
    Ciana P; Braliou GG; Demay FG; von Lindern M; Barettino D; Beug H; Stunnenberg HG
    EMBO J; 1998 Dec; 17(24):7382-94. PubMed ID: 9857194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer promoted by the oncoprotein v-ErbA may be due to subcellular mislocalization of nuclear receptors.
    Bonamy GM; Guiochon-Mantel A; Allison LA
    Mol Endocrinol; 2005 May; 19(5):1213-30. PubMed ID: 15650025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function.
    Piedrafita FJ; Ortiz MA; Pfahl M
    Mol Endocrinol; 1995 Nov; 9(11):1533-48. PubMed ID: 8584031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of the cell-specific activity of v-erb A in quail myoblasts.
    Cassar-Malek I; Marchal S; Rochard P; Wrutniak C; Samarut J; Cabello G
    Oncogene; 1997 Mar; 14(9):1099-108. PubMed ID: 9070659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.